Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$4.02 -3.6%	$3.95	$3.04 ▼ $8.10	$228.14M	1.21	167,046 shs	88,157 shs
LRMR Larimar Therapeutics	$3.21 -3.3%	$2.66	$1.61 ▼ $9.97	$212.57M	0.86	842,629 shs	480,386 shs
MDWD MediWound	$20.46 +2.0%	$20.19	$14.14 ▼ $22.51	$216.70M	0.32	64,521 shs	77,898 shs
NRXP NRx Pharmaceuticals	$2.94 -3.0%	$3.03	$1.10 ▼ $6.01	$52.39M	1.59	423,032 shs	182,185 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	-3.60%	-1.47%	+0.75%	+21.82%	-51.27%
LRMR Larimar Therapeutics	-3.31%	-5.03%	+17.15%	+68.50%	-68.19%
MDWD MediWound	+2.04%	+2.15%	+5.30%	+19.65%	+0.64%
NRXP NRx Pharmaceuticals	-2.97%	-8.41%	-8.98%	+52.33%	+23.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	3.3258 of 5 stars	3.5	2.0	2.7	3.3	1.3
LRMR Larimar Therapeutics	2.2839 of 5 stars	3.6	2.0	3.0	1.7	0.0
MDWD MediWound	1.6492 of 5 stars	3.5	1.0	1.6	0.8	0.6
NRXP NRx Pharmaceuticals	2.6292 of 5 stars	3.6	4.0	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	3.00	Buy	$8.00	99.00% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	476.32% Upside
MDWD MediWound	3.00	Buy	$32.25	57.62% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	869.39% Upside

Current Analyst Ratings Breakdown

Latest NRXP, MDWD, BTMD, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$197.19M	1.12	$0.74 per share	5.44	($2.78) per share	-1.45
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
MDWD MediWound	$20.22M	10.94	N/A	N/A	$2.89 per share	7.08
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.16M	$0.61	6.59	7.44	N/A	10.93%	-19.44%	20.12%	8/6/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)

Latest NRXP, MDWD, BTMD, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BTMD biote	$0.06	N/A	N/A	N/A	$49.52 million	N/A
8/13/2025	Q2 2025	MDWD MediWound	-$0.55	N/A	N/A	N/A	$5.68 million	N/A
8/13/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.4877	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/7/2025	Q1 2025	BTMD biote	$0.06	$0.08	+$0.02	$0.37	$47.25 million	$48.99 million
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	1.42	1.14
LRMR Larimar Therapeutics	N/A	7.48	7.48
MDWD MediWound	N/A	2.15	1.99
NRXP NRx Pharmaceuticals	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
LRMR Larimar Therapeutics	91.92%
MDWD MediWound	46.83%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
LRMR Larimar Therapeutics	4.50%
MDWD MediWound	9.20%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	54.71 million	41.58 million	Not Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable

NRXP, MDWD, BTMD, and LRMR Headlines

Recent News About These Companies

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment

July 17 at 3:20 AM | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $28.50 Average Target Price from Analysts

July 14, 2025 | americanbankingnews.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Buy" by Brokerages

July 11, 2025 | marketbeat.com

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

July 9, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

July 9, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Down 0.3% - Here's What Happened

July 8, 2025 | marketbeat.com

NRX Pharmaceuticals Inc Ordinary Shares NRXP - Morningstar

July 3, 2025 | morningstar.comM

NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100 - Benzinga

July 2, 2025 | benzinga.com

NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

June 30, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100

June 30, 2025 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NRXP) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional ...

June 27, 2025 | nasdaq.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 27, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 26, 2025 | financial-news.co.uk

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

June 26, 2025 | prnewswire.com

NRX Pharmaceuticals Inc News (NRXP) - Investing.com

June 24, 2025 | investing.com

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

June 24, 2025 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

June 23, 2025 | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral Capital

June 20, 2025 | marketbeat.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 17, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 16, 2025 | financial-news.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP, MDWD, BTMD, and LRMR Company Descriptions

biote NASDAQ:BTMD

$4.02 -0.15 (-3.60%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.02 0.00 (0.00%)

As of 07/18/2025 06:03 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Larimar Therapeutics NASDAQ:LRMR

$3.21 -0.11 (-3.31%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.22 +0.01 (+0.31%)

As of 07/18/2025 06:17 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

MediWound NASDAQ:MDWD

$20.46 +0.41 (+2.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$20.45 -0.01 (-0.05%)

As of 07/18/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

NRx Pharmaceuticals NASDAQ:NRXP

$2.94 -0.09 (-2.97%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.00 +0.06 (+2.21%)

As of 07/18/2025 07:57 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time